Cargando…
Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study
AIMS/INTRODUCTION: Medication adherence, which is decreased by a poor understanding of medications, has a close association with blood glucose level in patients with type 2 diabetes. However, a relationship between the understanding of antidiabetic medication and blood glucose level in patients with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400207/ https://www.ncbi.nlm.nih.gov/pubmed/30136448 http://dx.doi.org/10.1111/jdi.12916 |
_version_ | 1783399917503381504 |
---|---|
author | Sakai, Ryosuke Hashimoto, Yoshitaka Ushigome, Emi Okamura, Takuro Hamaguchi, Masahide Yamazaki, Masahiro Oda, Yohei Fukui, Michiaki |
author_facet | Sakai, Ryosuke Hashimoto, Yoshitaka Ushigome, Emi Okamura, Takuro Hamaguchi, Masahide Yamazaki, Masahiro Oda, Yohei Fukui, Michiaki |
author_sort | Sakai, Ryosuke |
collection | PubMed |
description | AIMS/INTRODUCTION: Medication adherence, which is decreased by a poor understanding of medications, has a close association with blood glucose level in patients with type 2 diabetes. However, a relationship between the understanding of antidiabetic medication and blood glucose level in patients with type 2 diabetes is unclear. Here, we aimed to investigate the relationship between the understanding of antidiabetic medication and blood glucose level in patients with type 2 diabetes. MATERIALS AND METHODS: Lifestyle factors were evaluated by a questionnaire method, in the present cross‐sectional study. Poor understanding of antidiabetic medication (PUAD) was defined as a discrepancy between the answer and the actual use of oral antidiabetic medication on the questionnaire. Poor blood glucose level was defined as hemoglobin A1c ≥8%. To investigate the impact of PUAD on poor blood glucose level, propensity‐score matching analysis was used to remove the bias of confounding variables, including sex, age, log (duration of diabetes +1), body mass index, number of oral antidiabetic medications, smoking status, alcohol drinking, exercise, nephropathy, neuropathy, oral antidiabetic medications and insulin. RESULTS: Among 479 patients, 40 patients (8.4%) were categorized into the PUAD group. The hemoglobin A1c of patients with PUAD was higher than that of patients without (7.5 [1.3] vs 7.2 [0.9]%, P = 0.041). In the propensity‐matched 74 patients, PUAD was associated with poor blood glucose level (odds ratio 5.45, 95% confidence interval 1.54–25.8, P = 0.007) by logistic regression analysis. CONCLUSION: A poor understanding of antidiabetic medication is associated with poor blood glucose level in patients with type 2 diabetes. |
format | Online Article Text |
id | pubmed-6400207 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-64002072019-03-14 Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study Sakai, Ryosuke Hashimoto, Yoshitaka Ushigome, Emi Okamura, Takuro Hamaguchi, Masahide Yamazaki, Masahiro Oda, Yohei Fukui, Michiaki J Diabetes Investig Articles AIMS/INTRODUCTION: Medication adherence, which is decreased by a poor understanding of medications, has a close association with blood glucose level in patients with type 2 diabetes. However, a relationship between the understanding of antidiabetic medication and blood glucose level in patients with type 2 diabetes is unclear. Here, we aimed to investigate the relationship between the understanding of antidiabetic medication and blood glucose level in patients with type 2 diabetes. MATERIALS AND METHODS: Lifestyle factors were evaluated by a questionnaire method, in the present cross‐sectional study. Poor understanding of antidiabetic medication (PUAD) was defined as a discrepancy between the answer and the actual use of oral antidiabetic medication on the questionnaire. Poor blood glucose level was defined as hemoglobin A1c ≥8%. To investigate the impact of PUAD on poor blood glucose level, propensity‐score matching analysis was used to remove the bias of confounding variables, including sex, age, log (duration of diabetes +1), body mass index, number of oral antidiabetic medications, smoking status, alcohol drinking, exercise, nephropathy, neuropathy, oral antidiabetic medications and insulin. RESULTS: Among 479 patients, 40 patients (8.4%) were categorized into the PUAD group. The hemoglobin A1c of patients with PUAD was higher than that of patients without (7.5 [1.3] vs 7.2 [0.9]%, P = 0.041). In the propensity‐matched 74 patients, PUAD was associated with poor blood glucose level (odds ratio 5.45, 95% confidence interval 1.54–25.8, P = 0.007) by logistic regression analysis. CONCLUSION: A poor understanding of antidiabetic medication is associated with poor blood glucose level in patients with type 2 diabetes. John Wiley and Sons Inc. 2018-09-24 2019-03 /pmc/articles/PMC6400207/ /pubmed/30136448 http://dx.doi.org/10.1111/jdi.12916 Text en © 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Articles Sakai, Ryosuke Hashimoto, Yoshitaka Ushigome, Emi Okamura, Takuro Hamaguchi, Masahide Yamazaki, Masahiro Oda, Yohei Fukui, Michiaki Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study |
title | Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study |
title_full | Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study |
title_fullStr | Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study |
title_full_unstemmed | Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study |
title_short | Understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: At baseline date of the KAMOGAWA‐DM cohort study |
title_sort | understanding of antidiabetic medication is associated with blood glucose in patients with type 2 diabetes: at baseline date of the kamogawa‐dm cohort study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400207/ https://www.ncbi.nlm.nih.gov/pubmed/30136448 http://dx.doi.org/10.1111/jdi.12916 |
work_keys_str_mv | AT sakairyosuke understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy AT hashimotoyoshitaka understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy AT ushigomeemi understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy AT okamuratakuro understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy AT hamaguchimasahide understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy AT yamazakimasahiro understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy AT odayohei understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy AT fukuimichiaki understandingofantidiabeticmedicationisassociatedwithbloodglucoseinpatientswithtype2diabetesatbaselinedateofthekamogawadmcohortstudy |